Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Antibody production including different antibody production like monoclonal and polyclonal and others. This antibodies are ideally have core immune activity. The growing burden of different disease in Europe region is expected to drive the growth of antibody production in pharmaceutical and biotechnology companies, diagnostic laboratories, research institutes. In addition, rising rate of cancer and other disease has led the demand for the antibody production market. The market is expected to witness emerging growth in upcoming years.
The Europe market is significantly driven by rising incidence of infectious diseases in the region which has led the emerging demand for antibody production. Besides, increasing adoption of targeted immunotherapy is anticipated to contribute in the region’s market. Also, increasing r&d expenditure in pharmaceutical and biotechnological companies to produce innovative antibody products based on different disease will accelerate the market growth. Likewise, rising number of fast track and orphan drug designations is likely to contribute healthy growth in the market.
The exclusive COVID 19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the Europe antibody production market. In addition, complete analysis of changes on the Europe antibody production market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. COVID-19 had a positive impact on market as the demand for the production of new antibody was accelerated specifically for corona viruses.
The antibody production market comprises of different market segment like process, end user, class and geography.
The antibody production includes key process segment of upstream processing, downstream processing, ion exchange (iex) chromatography resins, hydrophobic interaction chromatography (hic) resins, multimodal chromatography resins, and filtration. Further, upstream processing includes bioreactors and consumables. Bioreactors is further sub segmented to large-scale bioreactors and single-use bioreactors (subs). Likewise, consumables includes media and reagents and buffers. Also, downstream processing is bifurcated to chromatography instruments and chromatography resins. Additionally filtration includes filtration systems and filtration consumables and accessories. The upstream processing is expected to witness growth at significant pace during the forecast period. The growing productivity for production of antibody by upstream processing is the key driving factor the growth of segment. In addition, downstream processing is anticipated to emerge huge demand in upcoming years. The downstream processing significantly provides an advantage accuracy, and efficient product
The antibody production market finds its end use in pharmaceutical and biotechnology companies, diagnostic laboratories and research institutes. The rising number of new pharmaceutical and biotechnology companies for the production of antibody is projected to propel the region’s market growth. Likewise, rising approval for antibody drugs in region’s market is boosting the segment growth. In addition, diagnostic laboratories and research institutes are expected to witness emerging growth during the forecast period as number of research activities are conducted for the antibody production which is the key factor driving the market growth in region.
The antibody production by class is available in market according to monoclonal antibodies, murine, chimeric, humanized and polyclonal antibodies. Monoclonal antibodies is expected to grow at significant pace during the forecast period. The increasing adoption for the segment in Europe region is anticipated to drive the growth of market. Beside increasing research in different research institute and rising requirement for the production of the monoclonal antibodies is expected to boost the market growth. Additionally, polyclonal antibodies is estimated to contribute healthy growth in market during the forecast period. The growth is due to growing product production and application is likely to contribute in market growth.
Europe antibody production market is studied for the following countries like Germany, U.K, France, Italy, Spain and Rest of Europe. Germany is expected to register major market for the Europe antibody production owing to emerging number of new manufacturer and rising demand for antibody production from various end use industries is expected to drive the growth of market. Besides, U.K followed by France are anticipated to register growth in positive way leading to growth of countries and ultimately boosting the Europe antibody production market
The key players in antibody production market are GE Healthcare (General Electric Company), Merck KGAA, Thermo Fisher Scientific, Inc., Sartorius AG, Pall Corporation (Danaher Corporation), Sigma-Aldrich Corporation (Merck KGAA), Eppendorf AG, Cellab GmbH, Integra Biosciences AG and Fibercell Systems Inc. among others.
April 2021: Harbour BioMed had presented a newly discovered fully human anti- B7H7 monoclonal antibody at American Association for Cancer Research. The anti- B7H7 monoclonal is a novel immune oncology antibody with potent anti-tumor activity generated using HBM proprietary H2L2 Harbour Mice platform
March 2021: Pionyr Immuno therapeutics had collaborated with Lonza to support the oncology product development. The collaboration will bring the Pionyr third pipeline development candidate for novel Myeloid Tuning target to clinical development. Also, Lonza Company will provide cell line development, process development, drug substance and drug product manufacturing for Pionyr’s monoclonal antibody candidate intended for oncology indications.
November 2020: Purolite Ltd had announced that the company will supply its protein A capture resin, Praesto Jetted A50 to WuXi Biologics for immediate use. The WuXi Biologics company will use the Praesto Jetted A50 to provide their customer for affinity chromatography resin for range of downstream processing for monoclonal antibody purification.
October 2020: IAVI and Serum Institute of India had announced an agreement with Merck KGaA, Germany to develop SARS CoV-2 neutralizing monoclonal antibodies (mAbs) and is co- invented by IAVI and Scripps Research as innovative interventions for COVID-19 pandemic.
The report analyses the antibody production market based on by process, end user, class and country. By process, the antibody production includes key segment of upstream processing, downstream processing, ion exchange (iex) chromatography resins, hydrophobic interaction chromatography (hic) resins, multimodal chromatography resins, and filtration. The antibody production market finds its end use in pharmaceutical and biotechnology companies, diagnostic laboratories and research institutes. The antibody production by class is available in market according to monoclonal antibodies, murine, chimeric, humanized and polyclonal antibodies. Europe antibody production market is studied for the following countries like Germany, U.K, France, Italy, Spain and Rest of Europe.
Why to buy this report:
